The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf), the first approved treatment for children with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. The gene therapy offers a new treatment option for this rare, inherited neurodevelopmental disorder, which causes progressive neurological deterioration and loss of developmental abilities.
Fayuvi is administered as a one-time intravenous infusion. It uses a modified, non-infectious adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the SGSH gene into cells, enabling them to produce sulfamidase and helping the body break down accumulated heparan sulphate.
The FDA assessed the treatment in an open-label, single-arm, multicentre clinical study involving paediatric patients with MPS IIIA. The evaluation included changes in cognitive scores among children aged two to five years. According to the agency, patients receiving Fayuvi maintained or improved cognitive function compared with an untreated historical control group. The findings suggest a potential benefit during a developmental period when the disease would otherwise be expected to cause a plateau and decline in cognitive abilities.
However, the evidence comes from a study without a concurrent control group, and further follow-up will be important in understanding the durability of the treatment’s benefits and its long-term safety.
Reported adverse reactions included elevated liver enzymes, nausea, vomiting, fever, reduced appetite, decreased white blood cell and platelet counts, and increased amylase. The FDA also highlighted the risk of thrombotic microangiopathy, a serious condition affecting small blood vessels, alongside a potential long-term risk of genetic material integration and tumour development.
| Receive ACNR updates by email |
Treatment must be administered in a suitably equipped healthcare setting. Patients receive corticosteroids starting one day before infusion and continuing for at least eight weeks afterwards.
The FDA granted Fayuvi Orphan Drug, Fast Track and Breakthrough Therapy designations before approving it for Ultragenyx Pharmaceutical. The decision marks a significant development in gene therapy for rare paediatric neurological diseases, although ongoing monitoring will be essential to establish its long-term clinical impact.
This news item has been summarised using AI and checked by humans before publication.
Sources
US Food and Drug Administration (FDA)
| Sign up for our online community for neurology specialists |

